NAI Reports 16% Increase in Private-Label Contract Manufacturing Sales for Fiscal Year Ending June 30, 2025

Reuters
2025/09/24
NAI Reports 16% Increase in Private-Label Contract Manufacturing Sales for Fiscal Year Ending June 30, 2025

Natural Alternatives International Inc. (NAI) has released its financial results for the fiscal year ending June 30, 2025. The company reported a notable increase in private-label contract manufacturing sales, which rose by 16% to $121.8 million, compared to $105.4 million in the previous fiscal year. This growth highlights the company's focus on expanding its services in providing private-label manufacturing for vitamins, minerals, herbal, and other nutritional supplements, as well as other healthcare products. NAI's revenue has historically been dependent on sales to two or three major private-label customers. The company continues to improve operational efficiencies and manage costs and business risks to enhance profitability. The report also includes a discussion of critical accounting estimates, particularly in revenue recognition, highlighting the importance of precise estimations in contracts with volume rebates. The company did not provide specific forward-looking guidance or detailed outlook in the report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NAI - Natural Alternatives International Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-029731), on September 23, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10